The Importance of Ischemia Modified Albumin in Chronic Hepatitis B and C
Objectives: In this study, it was aimed to investigate the ischemia modified albumin (IMA) and the IMA/albumin ratio (IMAR) and the relationship between these two parameters with fibrosis in patients with chronic hepatitis B (CHB), hepatitis B e antigen negative chronic infection (HBI) and chronic h...
Gespeichert in:
| Veröffentlicht in: | Viral hepatit dergisi 2021-08, Vol.27 (2), p.53-56 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 56 |
|---|---|
| container_issue | 2 |
| container_start_page | 53 |
| container_title | Viral hepatit dergisi |
| container_volume | 27 |
| creator | Şenol, Arzu Türkoğlu, Semra |
| description | Objectives: In this study, it was aimed to investigate the ischemia modified albumin (IMA) and the IMA/albumin ratio (IMAR) and the relationship between these two parameters with fibrosis in patients with chronic hepatitis B (CHB), hepatitis B e antigen negative chronic infection (HBI) and chronic hepatitis C (CHC). Materials and Methods: This prospective study included 80 patients with CHB, 50 patients with HBI, 30 patients with CHC and 60 control groups. IMA level was measured using rapid colorimetric analysis developed (albumin-cobalt binding test). IMAR was calculated. Results: Forty-two of the CHB cases were female and 38 were male (age range: 46.62±2.69). Thirty of the HBI patients were female and 20 were male (age range: 40.83±3.71). Ten of the cases with CHC were female, and 20 were male (age range: 41.35±3.58). Thirty-three of the control group were female and 27 were male (age range: 30.45±1.08). Serum IMA levels and IMAR, CHB, HBI, and CHC cases were statistically significantly higher than the control group (p |
| doi_str_mv | 10.4274/vhd.galenos.2021.2021-2-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2833273938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2833273938</sourcerecordid><originalsourceid>FETCH-LOGICAL-c214t-87b5cea4d96423988acfff8dbfd3311e2d32d499056ab99bcbde32dd984725ef3</originalsourceid><addsrcrecordid>eNotkFtLAzEQhYMoWGr_Q8Tn1M1lm-SxLmoLFV_qc8jVjXQ3a7IV_PdubWE4A8PhnOED4B5XS0Y4e_xp3fJTH3yfypJUBP8LIghfgRnBjCMiqbwGM0wrjiRj-BYsSommYoyvWM3rGdjsWw-33ZDyqHvrYQpwW2zru6jhW3IxRO_g-mCOXezhNE2bUx8t3PhBj3GMBT5B3TvY3IGboA_FLy57Dj5envfNBu3eX7fNeofs9NGIBDe19Zo5uWKESiG0DSEIZ4KjFGNPHCWOSVnVK22kNNY4P12cFIyT2gc6Bw_n3CGn76Mvo_pKx9xPlYoISgmnkorJJc8um1Mp2Qc15Njp_KtwpU7s1MROXdipE7aLKEz_AH9yZSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2833273938</pqid></control><display><type>article</type><title>The Importance of Ischemia Modified Albumin in Chronic Hepatitis B and C</title><source>Alma/SFX Local Collection</source><creator>Şenol, Arzu ; Türkoğlu, Semra</creator><creatorcontrib>Şenol, Arzu ; Türkoğlu, Semra</creatorcontrib><description>Objectives: In this study, it was aimed to investigate the ischemia modified albumin (IMA) and the IMA/albumin ratio (IMAR) and the relationship between these two parameters with fibrosis in patients with chronic hepatitis B (CHB), hepatitis B e antigen negative chronic infection (HBI) and chronic hepatitis C (CHC). Materials and Methods: This prospective study included 80 patients with CHB, 50 patients with HBI, 30 patients with CHC and 60 control groups. IMA level was measured using rapid colorimetric analysis developed (albumin-cobalt binding test). IMAR was calculated. Results: Forty-two of the CHB cases were female and 38 were male (age range: 46.62±2.69). Thirty of the HBI patients were female and 20 were male (age range: 40.83±3.71). Ten of the cases with CHC were female, and 20 were male (age range: 41.35±3.58). Thirty-three of the control group were female and 27 were male (age range: 30.45±1.08). Serum IMA levels and IMAR, CHB, HBI, and CHC cases were statistically significantly higher than the control group (p<0.05). However, in terms of IMA, IMAR, no statistically significant difference was found in the between CHB, HBI and CHC cases. In CHB and CHC, IMA and IMAR were statistically significantly higher in those with significant fibrosis than those with mild fibrosis (p<0.05). Conclusion: IMA and IMAR can be used as a marker in determining prognosis as an indicator of oxidative liver damage and in the evaluation of fibrosis (especially early detection of fibrosis).</description><identifier>ISSN: 1307-9441</identifier><identifier>EISSN: 2147-2939</identifier><identifier>DOI: 10.4274/vhd.galenos.2021.2021-2-1</identifier><language>eng</language><publisher>Ankara: Galenos Publishing House</publisher><subject>Age ; Antigens ; Cardiovascular disease ; Chronic illnesses ; Gender ; Hepatitis B ; Hepatitis C ; Ischemia ; Laboratories ; Liver cancer ; Liver diseases ; Normal distribution ; Patients ; Viruses</subject><ispartof>Viral hepatit dergisi, 2021-08, Vol.27 (2), p.53-56</ispartof><rights>2021. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-7682-0513 ; 0000-0002-8537-0195</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>Şenol, Arzu</creatorcontrib><creatorcontrib>Türkoğlu, Semra</creatorcontrib><title>The Importance of Ischemia Modified Albumin in Chronic Hepatitis B and C</title><title>Viral hepatit dergisi</title><description>Objectives: In this study, it was aimed to investigate the ischemia modified albumin (IMA) and the IMA/albumin ratio (IMAR) and the relationship between these two parameters with fibrosis in patients with chronic hepatitis B (CHB), hepatitis B e antigen negative chronic infection (HBI) and chronic hepatitis C (CHC). Materials and Methods: This prospective study included 80 patients with CHB, 50 patients with HBI, 30 patients with CHC and 60 control groups. IMA level was measured using rapid colorimetric analysis developed (albumin-cobalt binding test). IMAR was calculated. Results: Forty-two of the CHB cases were female and 38 were male (age range: 46.62±2.69). Thirty of the HBI patients were female and 20 were male (age range: 40.83±3.71). Ten of the cases with CHC were female, and 20 were male (age range: 41.35±3.58). Thirty-three of the control group were female and 27 were male (age range: 30.45±1.08). Serum IMA levels and IMAR, CHB, HBI, and CHC cases were statistically significantly higher than the control group (p<0.05). However, in terms of IMA, IMAR, no statistically significant difference was found in the between CHB, HBI and CHC cases. In CHB and CHC, IMA and IMAR were statistically significantly higher in those with significant fibrosis than those with mild fibrosis (p<0.05). Conclusion: IMA and IMAR can be used as a marker in determining prognosis as an indicator of oxidative liver damage and in the evaluation of fibrosis (especially early detection of fibrosis).</description><subject>Age</subject><subject>Antigens</subject><subject>Cardiovascular disease</subject><subject>Chronic illnesses</subject><subject>Gender</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Ischemia</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Normal distribution</subject><subject>Patients</subject><subject>Viruses</subject><issn>1307-9441</issn><issn>2147-2939</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNotkFtLAzEQhYMoWGr_Q8Tn1M1lm-SxLmoLFV_qc8jVjXQ3a7IV_PdubWE4A8PhnOED4B5XS0Y4e_xp3fJTH3yfypJUBP8LIghfgRnBjCMiqbwGM0wrjiRj-BYsSommYoyvWM3rGdjsWw-33ZDyqHvrYQpwW2zru6jhW3IxRO_g-mCOXezhNE2bUx8t3PhBj3GMBT5B3TvY3IGboA_FLy57Dj5envfNBu3eX7fNeofs9NGIBDe19Zo5uWKESiG0DSEIZ4KjFGNPHCWOSVnVK22kNNY4P12cFIyT2gc6Bw_n3CGn76Mvo_pKx9xPlYoISgmnkorJJc8um1Mp2Qc15Njp_KtwpU7s1MROXdipE7aLKEz_AH9yZSA</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Şenol, Arzu</creator><creator>Türkoğlu, Semra</creator><general>Galenos Publishing House</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-7682-0513</orcidid><orcidid>https://orcid.org/0000-0002-8537-0195</orcidid></search><sort><creationdate>20210801</creationdate><title>The Importance of Ischemia Modified Albumin in Chronic Hepatitis B and C</title><author>Şenol, Arzu ; Türkoğlu, Semra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c214t-87b5cea4d96423988acfff8dbfd3311e2d32d499056ab99bcbde32dd984725ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>Antigens</topic><topic>Cardiovascular disease</topic><topic>Chronic illnesses</topic><topic>Gender</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Ischemia</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Normal distribution</topic><topic>Patients</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Şenol, Arzu</creatorcontrib><creatorcontrib>Türkoğlu, Semra</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Viral hepatit dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Şenol, Arzu</au><au>Türkoğlu, Semra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Importance of Ischemia Modified Albumin in Chronic Hepatitis B and C</atitle><jtitle>Viral hepatit dergisi</jtitle><date>2021-08-01</date><risdate>2021</risdate><volume>27</volume><issue>2</issue><spage>53</spage><epage>56</epage><pages>53-56</pages><issn>1307-9441</issn><eissn>2147-2939</eissn><abstract>Objectives: In this study, it was aimed to investigate the ischemia modified albumin (IMA) and the IMA/albumin ratio (IMAR) and the relationship between these two parameters with fibrosis in patients with chronic hepatitis B (CHB), hepatitis B e antigen negative chronic infection (HBI) and chronic hepatitis C (CHC). Materials and Methods: This prospective study included 80 patients with CHB, 50 patients with HBI, 30 patients with CHC and 60 control groups. IMA level was measured using rapid colorimetric analysis developed (albumin-cobalt binding test). IMAR was calculated. Results: Forty-two of the CHB cases were female and 38 were male (age range: 46.62±2.69). Thirty of the HBI patients were female and 20 were male (age range: 40.83±3.71). Ten of the cases with CHC were female, and 20 were male (age range: 41.35±3.58). Thirty-three of the control group were female and 27 were male (age range: 30.45±1.08). Serum IMA levels and IMAR, CHB, HBI, and CHC cases were statistically significantly higher than the control group (p<0.05). However, in terms of IMA, IMAR, no statistically significant difference was found in the between CHB, HBI and CHC cases. In CHB and CHC, IMA and IMAR were statistically significantly higher in those with significant fibrosis than those with mild fibrosis (p<0.05). Conclusion: IMA and IMAR can be used as a marker in determining prognosis as an indicator of oxidative liver damage and in the evaluation of fibrosis (especially early detection of fibrosis).</abstract><cop>Ankara</cop><pub>Galenos Publishing House</pub><doi>10.4274/vhd.galenos.2021.2021-2-1</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-7682-0513</orcidid><orcidid>https://orcid.org/0000-0002-8537-0195</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1307-9441 |
| ispartof | Viral hepatit dergisi, 2021-08, Vol.27 (2), p.53-56 |
| issn | 1307-9441 2147-2939 |
| language | eng |
| recordid | cdi_proquest_journals_2833273938 |
| source | Alma/SFX Local Collection |
| subjects | Age Antigens Cardiovascular disease Chronic illnesses Gender Hepatitis B Hepatitis C Ischemia Laboratories Liver cancer Liver diseases Normal distribution Patients Viruses |
| title | The Importance of Ischemia Modified Albumin in Chronic Hepatitis B and C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T06%3A24%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Importance%20of%20Ischemia%20Modified%20Albumin%20in%20Chronic%20Hepatitis%20B%20and%20C&rft.jtitle=Viral%20hepatit%20dergisi&rft.au=%C5%9Eenol,%20Arzu&rft.date=2021-08-01&rft.volume=27&rft.issue=2&rft.spage=53&rft.epage=56&rft.pages=53-56&rft.issn=1307-9441&rft.eissn=2147-2939&rft_id=info:doi/10.4274/vhd.galenos.2021.2021-2-1&rft_dat=%3Cproquest_cross%3E2833273938%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2833273938&rft_id=info:pmid/&rfr_iscdi=true |